文献速递肝病消化道肿瘤与早癌

血清甲胎蛋白在肝细胞癌检出前10年以上即升高

Serum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-05-08

该研究基于日本3450例慢性肝病患者的15年超声监测数据,通过纵向判别分析连续AFP测量值构建肝细胞癌风险模型。模型在开发集中曲线下面积为0.78,可将患者分为高风险组(27.5例/1000人年)与低风险组(4.9例/1000人年),并在日本和苏格兰验证队列中表现相似。

要点

  • 连续AFP测量可提前10年以上识别肝细胞癌高风险患者。
  • 模型将患者分为高风险组(27.5例/1000人年)和低风险组(4.9例/1000人年)。
  • 模型在肝硬化患者及多国验证队列中表现相似。

核心结论

  • 基于血清AFP随时间变化的模型可识别慢性肝病患者的肝细胞癌风险,并区分高、低风险组。

研究设计与样本

  • 研究收集日本1998年3月至2014年4月3450例接受超声监测的慢性肝病患者数据,中位随访8.83年。
  • 对连续AFP测量值(中位每人56次,约每3个月一次)进行纵向判别分析以构建风险模型。
  • 模型在日本两个队列(404例和2754例)及苏格兰一个队列(1596例)中验证。

主要发现

  • 中位随访6.60年期间,413例患者检出肝细胞癌,中位肿瘤直径1.8 cm。
  • 开发集中模型识别肝细胞癌的曲线下面积为0.78,正确识别74.3%的进展为肝细胞癌患者和72.9%的未进展患者。
  • 模型总体正确分类73.1%的患者,高风险组肝细胞癌发生率为27.5例/1000人年,低风险组为4.9例/1000人年。
  • 模型在肝硬化患者中表现相似,验证队列结果与开发集相似。

临床怎么用

  • 可利用连续AFP测量值的变化评估慢性肝病患者肝细胞癌风险,辅助筛选需加强监测的高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Ultrasound (US)-based screening has been recommended for patients with an increased risk of hepatocellular carcinoma (HCC). US analysis, however, is limited in patients who are obese or have small tumors. The addition of serum level of α-fetoprotein (AFP) measurements to US analysis can increase detection of HCC. We analyzed data from patients with chronic liver disease, collected over 15 years in an HCC surveillance program, to develop a model to assess risk of HCC. METHODS: We collected data from 3450 patients with chronic liver disease undergoing US surveillance in Japan from March 1998 through April 2014, and followed them up for a median of 8.83 years. We performed longitudinal discriminant analysis of serial AFP measurements (median number of observations/patient, 56; approximately every 3 months) to develop a model to determine the risk of HCC. We validated the model using data from 2 cohorts of patients with chronic liver disease in Japan (404 and 2754 patients) and 1 cohort in Scotland (1596 patients). RESULTS: HCC was detected in 413 patients (median tumor diameter, 1.8 cm), during a median follow-up time of 6.60 years. In the development data set, the model identified patients who developed HCC with an area under the curve of 0.78; it correctly identified 74.3% of patients who did develop HCC, and 72.9% of patients who did not. Overall, 73.1% of patients were classified correctly. The model could be used to assign patients to a high-risk group (27.5 HCCs/1000 patient-years) vs a low-risk group (4.9 HCCs/1000 patient-years). A similar performance was observed when the model was used to assess patients with cirrhosis. Analysis of the validation cohorts produced similar results. CONCLUSIONS: We developed and validated a model to identify patients with chronic liver disease who are at risk for HCC based on change in serum AFP level over time. The model could be used to assign patients to high-risk vs low-risk groups, and might be used to select patients for surveillance.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hughes DM, Berhane S, Emily de Groot CA, et al. Serum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020. PMID: 32389887. doi:10.1016/j.cgh.2020.04.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。